ProPhase Labs Announces Board and Officer Changes
Ticker: PRPH · Form: 8-K · Filed: Feb 13, 2025 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0005, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, officer-appointment
TL;DR
ProPhase Labs reshuffled its board and exec team, expect new strategies.
AI Summary
ProPhase Labs, Inc. announced on February 7, 2025, changes related to its board of directors and officers. The filing indicates a departure of directors or certain officers, the election of new directors, and the appointment of certain officers, along with updates to compensatory arrangements for these individuals.
Why It Matters
Changes in a company's leadership and compensation structures can signal shifts in strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer
- Delaware (jurisdiction) — State of incorporation
- February 7, 2025 (date) — Date of earliest event reported
FAQ
What specific roles were affected by the director and officer changes?
The filing indicates a departure of directors or certain officers, the election of directors, and the appointment of certain officers, but does not specify the exact roles affected in this summary.
Were there any specific reasons cited for the departure of directors or officers?
The filing does not provide specific reasons for the departure of directors or officers in the provided text.
What are the new compensatory arrangements for the appointed officers?
The filing mentions compensatory arrangements of certain officers but does not detail the specifics of these arrangements in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 7, 2025.
What is the principal executive office address for ProPhase Labs, Inc.?
The principal executive offices are located at 711 Stewart Avenue, Suite 200, Garden City, New York 11530.
Filing Stats: 908 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-02-13 17:00:27
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
- $100,000 — erformance-based bonus in the amount of $100,000 for his activities in Q1 2025, includin
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-25-006473.txt ( ) — 211KB
- prph-20250207.xsd (EX-101.SCH) — 3KB
- prph-20250207_lab.xml (EX-101.LAB) — 33KB
- prph-20250207_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 PROPHASE LABS, INC. (Exact name of Company as specified in its charter) Delaware 000-21617 23-2577138 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 711 Stewart Avenue , Suite 200 G arden 11530 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (215) 345-0919 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. ProPhase Labs, Inc. (the "Company") is in final stages of negotiation with Stuart Hollenshead to be the new Chief Operating Officer of the Company. Mr. Hollenshead currently serves as CEO of 10PM Curfew, one of the largest and fastest-growing female-centric media platforms, and was previously Chief Operating Officer and Chief Business Officer of Barstool Sports. With the repositioning of the Company as a consumer products company, the Company believes that Mr. Hollenshead will be well suited as Chief Operating Officer given his extensive experience at world class marketing companies. Following the successful sale of Pharmaloz Manufacturing, Inc, Jed Latkin, Chief Operating Officer of the Company, provided notice to the Company on February 7, 2025, that he would be leaving the Company effective February 14, 2025 to pursue other business opportunities. Mr. Latkin's departure is not related to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Mr. Latkin will continue to serve as a consultant to the Company on a project-by-project basis following his departure as Chief Operating Officer. In connection with his transition, Mr. Latkin is expected to receive a performance-based bonus in the amount of $100,000 for his activities in Q1 2025, including his work on the previously announced sale of Pharmaloz Manufacturing, Inc. and Mr. Latkin's other activities for the Company in Q1 2025, to be paid on terms and conditions to be mutually agreed upon between the parties. The Company thanks Mr. Latkin for his contributions and leadership during his tenure and looks forward to continuing its relationship with him in his consulting capacity. Forward-Looking This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K other than statements of historical fact are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the expected timing and payment of compensation to Mr. Latkin, the continued consulting relationship with Mr. Latkin, and the expected appointment of Stuart Hollenshead as the Chief Operating Officer of the Company. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and the negative of such terms or other similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are based on the Company's current expectati